Early treatment with cholesterol-lowering statins is associated with a 15 percent reduction in the ten-year risk of dementia for patients diagnosed with type-2 diabetes.
Registry Data Tracks Patients
The investigation analyzed registry data covering many individuals who had not received statin therapy prior to 2006 and subsequently received a type-2 diabetes diagnosis between that year and 2019, with follow-up tracked through 2021.
Researchers divided the patient population into three distinct groups based on the timing of their medication:
- Patients who received no statin treatment within five years of their diabetes diagnosis.
- Patients who initiated statin therapy within the first year following diagnosis.
- Patients who started statin treatment within five years after their diabetes diagnosis.
Measuring the Ten-Year Risk Reduction
Data evaluation revealed that early statin treatment within the first year post-diagnosis correlated with a 15 percent lower risk of developing dementia over a ten-year period compared to receiving no statin therapy.
Patients who began treatment later within the five-year window experienced a ten percent reduction in risk.
Weighing Cardiovascular and Neurological Benefits
Statins rank among the most frequently prescribed medications.
The drug class functions by blocking a specific liver enzyme responsible for producing low-density lipoprotein (LDL) cholesterol, which protects patients against heart attacks, strokes, and related vascular events. Because type-2 diabetes inherently elevates a patient’s vulnerability to vascular deterioration, controlling circulating lipids is already a standard clinical recommendation to prevent cardiovascular events.
Ternhamar stated that among individuals developing type-2 diabetes, statin use tied to a lower risk of dementia, particularly when therapy began early.
Despite established guidelines encouraging cholesterol management for diabetes patients, Ternhamar pointed out that statins remain underutilized in clinical practice. Because the medications are relatively inexpensive, the findings provide an additional rationale for clinicians to prescribe them promptly to individuals managing both type-2 diabetes and elevated LDL cholesterol.
Understanding Observational Boundaries
The investigative team emphasized that the findings stem from an observational study design. Consequently, the research points to an association rather than a direct cause-and-effect relationship, meaning further clinical investigations are required to confirm the precise mechanisms driving the risk reduction.
Keep reading